Archive: 15/11/2016

New drug beats standard therapy in advanced kidney cancer

An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase ...

page 1 from 11